SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

Concord Drugs

BSE: 538965 28 Jun 2025
Healthcare
₹ 29.99
Concord Drugs Limited specializes in Pharmaceuticals within the Healthcare sector.

Concord Drugs - Share Price & Details

Market Cap
₹30.5
High /Low
45.0 / 26.1
Stock P/E
89.6
Book Value
₹34.1
Dividend Yield
0.0
ROCE
5.3
ROE
₹1.0
Face Value
10.0
PEG Ratio
NA
EVEBITDA
₹11.4
Debt
17.2
CMP / FCF
46.6
Debt to equity
₹0.5
NP Ann
0.34
High price all time
91.2
Piotroski score
₹6.0
Graham Number
16.2
No. Eq. Shares
1.0
Net CF
₹-0.02
Net profit
0.34
Price to book value
0.89
Interest Coverage
₹1.34
Low price all time
11.7
Industry PE
32.0
Reserves
₹24.1
Free Cash Flow
₹1.39

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
Concord Drugs LimitedNANANANA30.589.6
Vineet Laboratories Limited154.58-105.25140.76-11.4227.7
Global Longlife Hospital and RNANANANA27.5137.0

Peer Comparison Chart


About Concord Drugs

Concord Drugs Limited, with Security Code 538965, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Concord Drugs Faces Technical Shift Amidst Declining Performance and Valuation Opportunities

(05 Jun 2025)
Concord Drugs, a microcap in the Pharmaceuticals & Biotechnology sector, has recently experienced a change in its evaluation, reflecting a shift in its...
Read more →

Concord Drugs Adjusts Valuation Amid Mixed Performance and Market Challenges

(27 May 2025)
Concord Drugs, a microcap company in the Pharmaceuticals & Biotechnology sector, has recently seen an evaluation adjustment in its stock valuation grade.
Read more →

Concord Drugs Standalone March 2025 Net Sales at Rs 7.96 crore, down 44.95% Y-o-Y

(27 May 2025)
Net Sales at Rs 7.96 crore in March 2025 down 44.95% from Rs. 14.47 crore in March 2024. Story continues below Advertisement.
Read more →

Concord Drugs Reports Mixed Financial Results Amid Sales Decline in May 2025

(24 May 2025)
Concord Drugs has released its financial results for the quarter ending March 2025, showing a significant improvement in Profit After Tax,...
Read more →

Concord Drugs reports consolidated net profit of Rs 0.04 crore in the March 2025 quarter

(24 May 2025)
Sales decline 33.57% to Rs 10.39 crore. Net profit of Concord Drugs reported to Rs 0.04 crore in the quarter ended March 2025 as against net loss of Rs 0.34...
Read more →

Q4 Results Highlights: GNFC profit rises 65% YoY; JSW Steel beats profit estimates

(24 May 2025)
Q4 Results Highlights: The fourth quarter earnings season is underway and as many as 10 important names like Ashok Leyland, JSW Steel,...
Read more →